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Background
•

Anaplastic thyroid cancer (ATC) occurs in less than 2% of all thyroid cancer
cases, and it is almost uniformly lethal with an average median survival of
6 months (Manikas et al; JAMA Oncol, 2020)

•

ATC is very aggressive and spreads rapidly within the neck and
metastasizes to distant parts of the body, which makes it resistant to
standard therapy (surgery, radioactive iodine therapy and chemotherapy)
(Zhang et al; EJMC, 2022)

•

The mutational landscape of ATC is very complex compared to other forms
of thyroid cancer, including Papillary (PTC) and Follicular (FTC), due to
multiple mutations in oncogenes and tumor suppressors (Cancer Genome
Atlas Research N; Cell, 2014; Landa et al; JCI, 2016)

•

Thyroid cancers are rich in immune cells, making them a reasonable
candidate for immunotherapies (Varrichi et al; IJMS 2019)

•

To develop new therapeutic strategies, further studies determining the
immune cell composition of ATC that favors tumor progression are
required
Hypothetical scheme of immune contexture of thyroid cancer
(Varrichi et al; IJMS 2019)

Summary
•

ATC tumor microenvironment is highly enriched with exhausted CD4+ T cells expressing PD-1,
LAG3 and CTLA-4

•

ATC tumors are infiltrated with immunosuppressive myeloid cells, cDC2 and M2 macrophages,
expressing high levels of PDL1

•

Treg cells changed phenotype towards inflammatory Th17 cells in ATC

Future directions
• Assess the contribution of immune cells to ATC pathogenesis
• Evaluate the efficacy of cell-targeted and immune checkpoint blockade therapy in ATC
model
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